Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 12 clinical trials
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors

refractory non-small cell lung cancer (NSCLC), and advanced clear cell renal cell carcinoma (ccRCC). ABBV-CLS-484 will also be administered at the determined recommended dose in combination with a PD-1

  • 11 views
  • 22 Mar, 2022
  • 8 locations
Dupilumab_Metastatic NSCLC

. For Phase 2, to determine the effect of adding IL-4Ra blockade to PD-(L)1 blocking agents in patients with relapsed/refractory NSCLC, who have progressed on prior PD-(L)1 agents

  • 0 views
  • 16 Oct, 2021
  • 1 location
Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer

This phase II trial studies how well atezolizumab and cobimetinib work in treating patients with non-small cell lung cancer that has spread to other places in the body (metastatic), has come back (recurrent), or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the …

metastasis
monoclonal antibodies
measurable disease
tumor cells
monoclonal antibody therapy
  • 54 views
  • 05 Mar, 2022
  • 7 locations
Ph I/II Trial of Systemic VSV-IFN -NIS and Pembrolizumab in Refractory NSCLC and NEC

expansion portion will use one-sample binomial designs to assess the efficacy of the combination in patients with refractory NSCLC or NEC. The optimal dose (RP2D) determined in the dose escalation portion

pembrolizumab
solid tumour
measurable disease
immune checkpoint inhibitor
cancer chemotherapy
  • 7 views
  • 20 Oct, 2021
  • 1 location
Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography

This pilot research trial studies the effects of dexamethasone in patients with non-small cell lung cancer that has not responded after previous treatment. Drugs such as dexamethasone can affect how tumors grow and respond to treatments. Imaging tests, such as fluoro-L-thymidine (FLT) positron emission tomography , use a small amount …

diabetes
tumor cells
neutrophil count
biomarker analysis
lung cancer
  • 12 views
  • 27 Apr, 2022
  • 1 location
Allogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients

Objectives: To determine the safety, tolerability, and efficacy of allogeneic PB103 in patients with IIIb/IV or refractory non-small-cell lung cancer

neutrophil count
lung carcinoma
serum bilirubin level
platelet count
  • 0 views
  • 03 Sep, 2021
  • 1 location
Pixatimod (PG545) Plus Nivolumab in PD-1 Relapsed/Refractory Metastatic Melanoma and NSCLC and With Nivolumab and Low-dose Cyclophosphamide in MSS Metastatic Colorectal Carcinoma (mCRC)

combination with low-dose cyclophosphamide, Cohort 2: PD-1 relapsed/refractory melanoma, and Cohort 3: PD-1 relapsed/refractory NSCLC.

BRAF
pembrolizumab
nivolumab
EGFR
squamous cell carcinoma
  • 0 views
  • 27 Apr, 2022
  • 1 location
A Randomised Trial of Chemotherapy Plus Surgery for Recurrent Non-Small Cell Lung Cancer (CCODG-NSCLC)

clinical oncology, either a single format or given as combinations followed by surgery are effective in the treatment of relapsed and refractory non-small cell lung cancer patients.

carboplatin
cancer chemotherapy
docetaxel
lung cancer
  • 1 views
  • 11 May, 2022
  • 3 locations
Immunopheresis Alone or in Combination With Paclitaxel or Atezolizumab in Non-small Cell Lung Cancer (NSCLC).

advanced, refractory NSCLC and to detect a potential disease control signal when employed in combination with low dose chemotherapy (ie, paclitaxel), immunotherapy (ie, atezolizumab) in patients who

  • 0 views
  • 26 Jan, 2021
  • 3 locations
A Study of CM24 in Combination With Nivolumab in Adults With Advanced Solid Tumors

-small cell lung cancer (NSCLC) (Part B), and metastatic pancreatic cancer (Part C) to evaluate the safety and tolerability of CM-24 in combination with nivolumab. In Part C of the study nab-paclitaxel

nivolumab
brain metastases
paclitaxel
adenocarcinoma
measurable disease
  • 9 views
  • 12 May, 2022
  • 6 locations